Item no. |
ANOG-MO-C40009A |
Manufacturer |
Anogen
|
Amount |
0.5mg |
Category |
|
Type |
Antibody Monoclonal |
Format |
Aff. Pur |
Applications |
WB, IHC, NT |
Clone |
TB21 |
Specific against |
Human (Homo sapiens) |
Host |
Mouse |
Isotype |
IgG1 kappa |
Protein Family |
Cytokine, Growth Factors |
ECLASS 10.1 |
42030590 |
ECLASS 11.0 |
42030590 |
UNSPSC |
12352203 |
Similar products |
TGF-b |
Available |
|
Description |
Mouse monoclonal antibody to human Transforming Growth Factor beta (TGF-beta) |
Target Protein |
Human TGF-beta |
Immunogen |
TGF-beta from human platelets |
Specificity |
Western blotting demonstrated that this antibody reacts with the dimeric (25 kDa) and monomeric (12.5 kDa.) forms of TGF-beta under both non-reducing and reducing conditions respectively. This antibody recognizes both human platelet-derived and recombinant TGF-beta in ELISA. |
Purification |
Protein G affinity purified |
Species Reactivity |
Human, other species not tested |
Myeloma |
Sp2/0-Ag14 |
Background |
Transforming growth factor beta (TGF-beta) has three isoforms (TGF-beta1, TGF-beta2, and TGF-beta3) with similar functions. The cytokine is a homodimer linked by disulfide bind. Inside cells, the cytokine forms a small latent complex with latent associated peptide (LAP). This small complex binds to latent TGF-beta binding protein (LTBP) to be secreted to extra-cellular matrix. Disassociation of the latent proteins from TGF-beta results in the release of the cytokine to its receptor. The process is called activation, which can be influenced by various factors, including proteases, metalloproteases, extreme pH, mild acidic condition, reactive oxygen species and integrins. TGF-beta is an anti-proliferation factor in normal cells. It increases the synthesis of p15 and p21, which can block the cyclin: CDK complex, and causes cells to stop at G1 phase. The cytokine can induce apoptosis through both SMAD and DAXX pathways. In cancer cells, TGF-beta signaling is altered and TGF-beta no longer stops cell proliferation. |
Formulation |
Lyophilized from a solution in 0.01M PBS, pH 7.0 |
Reconstitution |
Double distilled water is recommended to adjust the final concentration to 1.00mg/mL. |
Application info |
Neutralizing: This antibody neutralizes TGF-beta activity in vitro and in vivo. In an inhibition assay of CCL/64 cell growth and in a NRK-49F colony forming assay, the antibody neutralized TGF-beta bioactivities. The effect of micro-injection of this antibody into one blastomere of two cell stage Xenopus embryos indicated that it was also able to neutralize the bioactivity of TGF-beta in vivo. IHC: This antibody has been used to demonstrate TGF-beta in ovine ovarian tissue and human breast carcinoma at a dilution of 1:1000. As a consequence of the intense staining of the erythrocytes, it is possible to locate a single cell within the ovarian stroma, making it useful in locating very fine capillary networks within tissue. Western Blot: This antibody when used at concentration of 5-20ng/mL will allow visualization of 100ng/lane of TGF-beta. |
Research Area |
Growth Factors and Their Receptors, Angiogenesis |
Storage |
Store at -20C |
Reference |
Crawford, S. E. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 93:1159-1170 (1998) Biological characterization of a monoclonal antibody TB21 against human transforming growth factor-beta 1. Acta Biologiae Experimentalis Sinica Vol. 26, No. 2 June (1993). |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.